Field & Main Bank grew its stake in shares of Amgen (NASDAQ:AMGN) by 9.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,153 shares of the medical research company’s stock after buying an additional 345 shares during the quarter. Field & Main Bank’s holdings in Amgen were worth $708,000 at the end of the most recent quarter.
Other institutional investors also recently bought and sold shares of the company. Barrow Hanley Mewhinney & Strauss LLC raised its position in shares of Amgen by 110.7% during the 4th quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 647 shares of the medical research company’s stock valued at $113,000 after buying an additional 340 shares in the last quarter. Taylor Hoffman Wealth Management purchased a new stake in shares of Amgen during the 4th quarter valued at $127,000. Horan Capital Advisors LLC. purchased a new stake in shares of Amgen during the 3rd quarter valued at $150,000. Welch Group LLC purchased a new stake in shares of Amgen during the 4th quarter valued at $148,000. Finally, Watermark Asset Management Inc. raised its position in shares of Amgen by 8,481.8% during the 4th quarter. Watermark Asset Management Inc. now owns 944 shares of the medical research company’s stock valued at $164,000 after buying an additional 933 shares in the last quarter. Hedge funds and other institutional investors own 86.39% of the company’s stock.
Get Amgen alerts:
Several analysts have recently weighed in on the stock. Leerink Swann restated a “market perform” rating on shares of Amgen in a research report on Friday, February 2nd. Atlantic Securities cut shares of Amgen from an “overweight” rating to a “neutral” rating and set a $187.01 price objective on the stock. in a research report on Monday, February 5th. Credit Suisse Group raised their price objective on shares of Amgen from $191.00 to $194.00 and gave the company a “neutral” rating in a research report on Friday, February 2nd. BidaskClub upgraded shares of Amgen from a “sell” rating to a “hold” rating in a research report on Thursday, January 18th. Finally, Mizuho increased their target price on shares of Amgen from $192.00 to $200.00 and gave the company a “buy” rating in a report on Monday, February 12th. Two analysts have rated the stock with a sell rating, fourteen have given a hold rating and ten have assigned a buy rating to the company. Amgen has an average rating of “Hold” and a consensus target price of $191.70.
Shares of Amgen stock opened at $167.98 on Monday. The firm has a market capitalization of $111,153.37, a price-to-earnings ratio of 13.35, a PEG ratio of 2.04 and a beta of 1.36. Amgen has a 12-month low of $152.16 and a 12-month high of $201.23. The company has a debt-to-equity ratio of 2.14, a quick ratio of 3.60 and a current ratio of 3.88.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, April 24th. The medical research company reported $3.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.24 by $0.23. The business had revenue of $5.55 billion for the quarter, compared to analyst estimates of $5.44 billion. Amgen had a net margin of 9.67% and a return on equity of 35.80%. The company’s revenue was up 1.6% on a year-over-year basis. During the same quarter last year, the firm earned $3.15 EPS. research analysts expect that Amgen will post 13.71 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, June 8th. Shareholders of record on Thursday, May 17th will be issued a $1.32 dividend. This represents a $5.28 dividend on an annualized basis and a yield of 3.14%. The ex-dividend date of this dividend is Wednesday, May 16th. Amgen’s dividend payout ratio (DPR) is presently 41.97%.
Amgen announced that its Board of Directors has authorized a share repurchase plan on Thursday, February 1st that authorizes the company to buyback $10.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to reacquire shares of its stock through open market purchases. Shares buyback plans are often a sign that the company’s management believes its stock is undervalued.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction on Friday, March 16th. The shares were sold at an average price of $189.75, for a total value of $289,368.75. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In the last three months, insiders sold 4,575 shares of company stock worth $818,330. Insiders own 0.27% of the company’s stock.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen (NASDAQ:AMGN).